[The statement of Polish Gynecological Society Experts on the etiology and treatment of recurrent vulvovaginal candidiasis]
Guideline
OA: green
CC0
AI-generated summary
This Polish Gynecological Society expert statement identifies fluconazole as a modern, effective, and well-tolerated treatment option for recurrent vulvovaginal candidiasis based on clinical trial data.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Vulvovaginal infection is the most common cause of gynecological problems in sexually active women. Knowledge about pharmacological properties of drugs used in treatment recurrent vulvovaginal candidiasis allows for tailoring therapy to each patient. Fluconazole is modern and up to date option for treatment of recurrent vulvovaginal candidiasis. Short- and long-term therapeutic efficacy of fluconazole was confirmed in numerous high reliability clinical trials. Good tolerance, high effectiveness and high level of patient's acceptance gives the specialist powerful and efficient tool for management of recurrent Candida infections.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:10:02.438825+00:00
License: CC0
· commercial use OK